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Abstract
MicroRNAs (miRNAs) play important roles in cancer development. By cloning and sequencing of a HPV16
+ CaSki cell small
RNA library, we isolated 174 miRNAs (including the novel miR-193c) which could be grouped into 46 different miRNA
species, with miR-21, miR-24, miR-27a, and miR-205 being most abundant. We chose for further study 10 miRNAs according
to their cloning frequency and associated their levels in 10 cervical cancer- or cervical intraepithelial neoplasia-derived cell
lines. No correlation was observed between their expression with the presence or absence of an integrated or episomal HPV
genome. All cell lines examined contained no detectable miR-143 and miR-145. HPV-infected cell lines expressed a different
set of miRNAs when grown in organotypic raft cultured as compared to monolayer cell culture, including expression of miR-
143 and miR-145. This suggests a correlation between miRNA expression and tissue differentiation. Using miRNA array
analyses for age-matched normal cervix and cervical cancer tissues, in combination with northern blot verification, we
identified significantly deregulated miRNAs in cervical cancer tissues, with miR-126, miR-143, and miR-145 downregulation
and miR-15b, miR-16, miR-146a, and miR-155 upregulation. Functional studies showed that both miR-143 and miR-145 are
suppressive to cell growth. When introduced into cell lines, miR-146a was found to promote cell proliferation. Collectively,
our data indicate that downregulation of miR-143 and miR-145 and upregulation of miR-146a play a role in cervical
carcinogenesis.
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Introduction
Cervical cancer is one of the most common cancers in women
worldwide, with an estimated global incidence of 470,000 new
cases and approximately 233,000 deaths per year [1,2]. Cervical
cancer is the leading cause of death from cancer in many low-
resource countries where widespread screening by cervical
cytology is unavailable. The incidence is lower in developed
countries as a consequence of cervical screening and of ongoing
active health education programs. Cervical cancer rates in the
United States were estimated as 10,370 new cases and 3,710
deaths in 2006 [3]. The causal relationship between high-risk
HPV (HR-HPV) infection and cervical cancer has been well
documented in epidemiological and functional studies. High-risk
HPVs, such as HPV16, HPV18, and HPV31, have been detected
in up to 99.7% of cervical squamous cell carcinomas and 94%–
100% of cervical adeno- and adenosquamous carcinomas [4,5].
The high-risk HPV oncoproteins, E6 and E7, contribute to
cervical carcinogenesis by inactivating the cellular tumor suppres-
sor proteins p53 and pRb, respectively [6–8].
miRNAs are regulatory, non-coding RNAs about 21–23
nucleotides in length and are expressed at specific stages of tissue
development or cell differentiation, and have large-scale effects on
the expression of a variety of genes at the post-transcriptional level.
Through base-pairing with its targeted mRNAs, a miRNA induces
RNA degradation or translational suppression of the targeted
transcripts [9,10]. Cellular miRNAs are transcribed by RNA
polymerase II as long, capped, polyadenylated primary miRNA
(pri-miRNA) transcripts bearing a stem-loop hairpin structure of
,80-nts [11]. Mature miRNAs result from the processing of pri-
miRNAs in two sequential cleavage steps mediated by two RNase
III enzymes, Drosha and Dicer [12]. Drosha, in complex with
DGCR8, cleaves the pri-miRNA at a specified distance (approx-
imately 11 bp) from the stem–single stranded RNA junction in the
nucleus to give a pre-miRNA of an ,60-nt hairpin with a 2-nt 39
overhang [13,14]. After the pre-miRNA is exported to the
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complex with dsRBD-containing partner HIV-1 TAR RNA-
binding protein (TRBP) [17], to remove the terminal loop, leaving
a second 2-nt 39 overhang [18]. The resulting 21- to 23-nt miRNA
products contain a 2-nt 39 overhang at each strand and act as the
functional intermediates of RNAi that direct mRNA cleavage and
translational attenuation. Although their biological functions
remain largely unknown, recent studies suggest that miRNAs
contribute to the development of various cancers [19] and might
function as an important component of the cell’s natural defense
against viral infection [20–22]. It has been proposed that an unique
miRNA expression profile for a particular cancer would be a useful
biomarker for cancer diagnosis [23] and prognosis [24]. In this
study, we used various approaches to profile miRNA expression
from cervical cancer tissues and cervical cancer–derived cell lines as
well as from HPV-infected vaginal keratinocytes. We demonstrate
that a subset of miRNAs is significantly dysregulated in cervical
cancers and pre-neoplastic lesions.
Results
miRNA expression profile in cervical cancer cell lines
To investigate the expression profiles of miRNAs in cervical
cancer cells, we isolated total cell RNA from cervical cancer–
derived CaSki C-2 cells, which contain ,500 copies of the HPV16
genome per cell. The fractionated RNAs with sizes of 15–30 nts
were cloned and sequenced based on a published protocol [25].
Overall, we cloned a total of 174 miRNAs from 363 cDNA clones
which were categorized into 46 different miRNA species (Table 1),
with miR-21, miR-24, miR-27a, and miR-205 being most
abundant. No HPV16-derived miRNA was cloned in this
screening, all the miRNAs were cellular. Interestingly, we found
that some copies of the cloned miR-21 and miR-205 had
heterogenous 39 ends, with an extra C nucleotide on the 39 end
of 68% of the miR-21 copies and an extra U on the 39 end of 33%
of the miR-205 copies, presumably derived from wobble digestion
of the pre-miRNAs by Dicer (Fig. 1). In addition, a new subspecies
of miR-193, miR-193c (GenBank accession number: EF100863),
was identified three times from the screening and was verified by
northern blotting. The miR-193c subspecies differs from miR-
193b by one nucleotide at position nt 21 and by the lack of three
Us at the 39 end (miR-193b, 59-aacuggcccucaaagucccgcuuu-39;
miR-193c, 59-aacuggcccucaaagucccga-39). The expression profile
of the newly identified miR-193c which is 3-nt smaller than miR-
193b was similar to that of miR-21 in HeLa cells and 293 cells, but
less abundant than miR-27a. HeLa and 293 cells produced no
detectable miR-205 as a doublet as seen in CaSki cells (Fig. 2A).
Based on these cloning results, we further screened several
available cervical cancer cell lines with or without HPV infection
by northern blotting for the expression of 8 miRNAs with
relatively high cloning frequency and 2 miRNAs (miR-143 and
miR-145) which were not isolated in our cloning (Table 1). Eight
cervical cancer cell lines; two isolates of the W12 cell line (20861
with integrated HPV16 genomes and 20863 with episomal
HPV16 genomes) originally isolated from a cervical intraepithelial
neoplasia (CIN) biopsy tissues [26] and HaCaT cells (an
immortalized HPV-negative skin keratinocyte line) [27] were
examined for the expression of the 10 miRNAs. A paired total
RNAs from cervical cancer and adjacent normal cervical tissues
commercially obtained from Ambion were also compared. All cell
lines and cervical cancer tissues showed a similar miRNA
expression profile. This miRNA profile differed from normal
cervical tissues with reduced expression of miR-27a, miR-143, and
miR-145 (Fig. 2B). In contrast, the cervical cancer tissue and the
cell lines, except SiHa (HPV16
+), HeLa (HPV18
+), and C33A cells
(HPV
2), had increased expression of miR-205 when compared
with normal cervical tissue (Fig. 2B). SiHa, HeLa, and C33A cells
have no expression of miR-205. In all of the cell lines, expression
of the miR-143 and -145 was less than what was observed in the
cervical cancer tissue. Despite the presence of some differences in
the expression of individual miRNA from one cell line to another,
we were unable to specify an expression profile of those detected
miRNAs in correlation to the presence of integrated or episomal
HPV genomes. The downregulation of miR-143, which is derived
from the same miRNA precursor of miR-145 [28], was further
confirmed to be cancer-specific by comparing its expression in
cervical cancer tissues to normal cervix (Fig. 2C).
miRNA expression profile in normal and cancerous
cervical tissues
Since our cloning approach has a limitation in the isolation of
low abundant miRNAs and northern blotting is limited by the
probe chosen, the two methods may not be the best to distinguish
a difference from one cell line to another in miRNA expression
profile. To further investigate whether miRNAs are differentially
expressed in cervical cancer tissues, we collected five pairs of age-
matched normal and cancerous cervical tissues and compared
Table 1. miRNA expression profile in HPV16-positive CaSki C-
2 cells by cDNA cloning.
miRNA
names
Frequency of
detection* miRNA names
Frequency of
detection*
miR-7 1 miR-92 1
miR-15a 2 miR-93 2
miR-16 7 miR-96 1
miR-17-5p 8 miR-106b 1
miR-19a 1 miR-130a 2
miR-19b 1 miR-130b 1
miR-20 3 miR-135b 1
miR-21 31 miR-141 3
miR-22 2 miR-151 1
miR-23a 5 miR-186 2
miR-24 10 miR-193b 1
miR-25 1 miR-193c 3
miR-26b 1 miR-203 2
miR-27a 29 miR-205 12
miR-27b 8 miR-301 2
miR-29a 3 miR-424 2
miR-29b 1 let-7a 6
miR-30a-3p 1 let-7b 2
miR-30a-5p 2 let-7d 2
miR-30d 1 let-7e 1
miR-31 3 let-7f 1
miR-33 1 let-7i 1
miR-34a 1
miR-34c 1 Total 174
*Isolation frequency from 363 cDNA clones. CaSki C-2 cells stably express a
hairpin-derived HPV16 E7 siRNA with no interfering function on HPV16 E7
expression (72). This screening also isolated 3 copies of the E7 siRNA.
doi:10.1371/journal.pone.0002557.t001
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455 miRNAs. Only four sample pairs qualified for the final
clustering analysis as determined by sample consistency analyses.
An expression abundance analysis, based on a signal density
$20,000, showed that both normal and cancerous cervical tissues
had abundant expression of miR-23a, miR-23b, let-7a, let-7c, and
let-7d, whereas high expression of miR-26a, miR-29a, miR-99a,
miR-100, miR-125b, miR-143, miR-145, miR195, and miR-199a
was only observed in normal cervical tissues, and high expression
of miR-16, miR-21, miR-205, and let-7f was only observed in
cervical cancer tissues, despite that relatively low levels of miR-16
and miR-21 were noticed from a homogeneous cell population in
some cell lines (Fig. 2B). Expression of miR-143 and miR-145
showed more than 2.7-fold reduction in the cervical cancer tissues.
Using a clustering analysis, we observed an significant increased
expression of 18 miRNAs in cervical cancer and 15 miRNAs in
normal cervix (Fig. 3A, miRNAs in red color) (P,0.05, t-test). For
verification, a set of selected miRNA probes were used to perform
a northern blot analysis for two normal and two cancer samples.
We were able to confirm that the cancer tissues had reduced
expression of miR-126 and miR-424, and increased expression of
miR-15b, miR-16, miR-146a, miR-155, and miR-223 (Fig. 3B
and 3C), after individual miRNA level in each sample was
quantified and normalized to U6 expression.
miRNA expression profile in HPV-infected, keratinocyte-
derived raft tissues
To investigate whether the observed miRNA signatures in
cervical cancer tissues are specific to cervical cancer, we examined
miRNA expression in pre-neoplastic lesions. The lack of conven-
tional cell cultures for HPV multiplication has largely restrained our
understanding of the HPV life cycle and pathogenesis. However,
infectious HPVs have been successfully produced from raft cultures
derived from human keratinocytes [29,30] and induction of pre-
neoplastic lesions in raft tissues by HPV infection with the
morphology similar to that of cervical intraepithelial neoplasia
[31] makes this system of great advantage for our studies. Using
miRNA array analyses, we compared the expression profiles of 455
human miRNAs in HPV18-infected primary human vaginal
keratinocytes (HVKs) in monolayer cultures and in stratified and
differentiated raft tissues. An expression abundance analysis, based
on a signal density $20,000, showed that miR-21, miR-23a, miR-
23b, miR-26a, miR-205, let-7c, and let-7f abundantly expressed in
HVKs both in monolayer cultures and raft cultures. Three miRNAs
abundantly expressed only in monolayer cultures (miR-24, miR-
29a, and miR-221) and 11 miRNAs abundantly expressed only in
the stratified and differentiated raft cultures (miR-27a, miR-27b,
miR-200b, miR-200c, miR-203, miR-638, let-7a, let-7b, let-7d, let-
7e, and let-7g). Using a clustering analysis, we further determined
that 16 miRNAs were upregulated (Fig. 4A, raft in red) and 25
miRNAs were downregulated (Fig. 4A, raft in green) in the raft
cultures when compared to the expression levels in the correspond-
ing monolayer cultures (P,0.05, t-test). To confirm the observa-
tions, the paired samples were analyzed for miRNA expression by
northern blotting using a set of specific miRNA probes (Fig. 4B and
4C). Quantitation of each miRNA level in each sample was
normalized to U6 expression. We confirmed that the expression of
miR-26b, miR-195, and miR-200c was increased in the raft
cultures,butthe expressionofmiR-143 and miR-145 wasdecreased
(Fig. 4B and 4C). The increased abundance of miR-200c showing
67% more expression in rafts than in monolayers (P,0.08) by array
analysis was verified by northern blotting. Although upregulation of
miR-15a and miR-223 and downregulation of miR-218 and miR-
424 were observed both in the rafts (pre-neoplastic lesions) and in
cervical cancer tissues, the majority of the miRNA expression
signatures showed no correlation between the two tissues (compare
Fig. 4A to Fig. 3A). However, downregulation of miR-146a was
noticed in the raft cultures rather than the upregulation seen in
cervical cancer tissues and was further confirmed by northern
blotting (Fig. 5), indicating that the upregulation of miR-146a
expression is cervical cancer-specific. In contrast, a slight increased
expression of miR-21 and miR-26b was observed in both the pre-
neoplastic lesions (HPV-infected rafts) and cervical cancer tissues
and thus their expression appears not cancer-specific (Fig. 5).
Reduced miR-143 and miR-145 in cervical lesions and
cervical cancer are suppressive in cervical cancer cell
growth
Having demonstrated a significant downregulation of miR-143
and miR-145 in cervical cancer and pre-neoplastic lesions, we
Figure 1. Wobble digestion of miRNAs by Dicer in CaSki cells. Arrows above the pre-miRNA indicate wobble-digestion sites on the pre–miR-
21 in A and pre-miR-205 in B, producing products with additional nucleotides on the 39 end. The sequences shown in red correspond to mature
miRNA while that shown in black is the portion of pre-miRNA which is removed during processing.
doi:10.1371/journal.pone.0002557.g001
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ment of cervical cancer. To address this question, synthetic miR-
143 and miR-145 precursors were transiently transfected into
HeLa cells and the effect of overexpression of their mature
miRNAs on HeLa cell growth was evaluated by cell counting. As
shown in Fig. 6, both miR-143 and miR-145 were found
suppressive (p,0.005 for miR-143 and p,0.008 of miR-145, t-
test) to HeLa cell growth. This suppressive effect on the cell growth
was not an immediate cell response; rather, two consecutive cell
transfections with each miRNA at an interval of 48 hrs were
needed. Data suggest that both miR-143 and miR-145 probably
need to be downregulated in cervical cells for tumor progression.
Figure 2. miRNA expression profile in cervical cancer cells determined by northern blot analysis. A. miR-193c expression in CaSki, HeLa,
and 293 cells. CaSki and its subclones C-V and C-2 cells [72] were compared with HeLa (HPV18
+) and 293 cells (HPV
2) for expression of miR-193c by
northern blotting. Total RNA (30 mg) from CaSki, HeLa, and 293 cells was separated in a 15% denaturing polyacrylamide gel, blotted onto a Gene
Screen-Plus membrane, and then probed separately with a sense (s) or an antisense (as) miR-193c probe. Subsequently, the membrane was reprobed
with antisense probes for miR-21, miR-27a, miR-205, or U6, respectively. B. miRNA expression in cervical cancer–derived cell lines. Total cell RNA
(30 mg) was extracted from various cell lines with or without HPV infection. Northern blotting was used to examine the expression of 10 miRNAs from
eight cancer cell lines, two W12 cell subclones, HaCaT cells, normal cervix, and cervical cancer tissues (Ambion). C. Downregulation of miR-143 in
cervical cancer tissues. Total RNAs from two pairs of normal (NT) cervix vs cervical cancer (Ca) tissues from clinical samples and one pair of normal
cervix and cervical cancer purchased from Ambion were compared for the expression of miR-143 by northern blotting. U6 was also blotted as an
internal control for sample loading in panel A, B, and C.
doi:10.1371/journal.pone.0002557.g002
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proliferation
Considering a 6-fold increase of miR-146a expression in
cervical cancer tissues, we hypothesized that a high level of
miR-146a might play a role in cervical cancer cell growth. Our
initial approach using anti-miR-146a inhibitors or using a
morphonino-oligo to block miR-146a maturation to knock down
miR-146a expression in cervical cancer cell lines failed to induce a
phenotypic effect (data not shown). To our surprise, we found that
all cervical cancer cell lines examined expressed no detectable
miR-146a (Fig. 7A). Subsequently, miR-146a was introduced by
transient transfection into HeLa cells, a HPV18
+ cervical cancer
cell line, and HCT116 cells, a colorectal cancer cell line (Fig. 7B).
A slow, but significantly enhanced cell proliferation of both HeLa
(p,0.009, t-test) and HCT116 (P,0.019, t-test) cells was noticed
in the presence of exogenous miR-146a. By calculation of the cell
counts from each group, we demonstrated that both HeLa cells
and HCT116 cells containing miR-146a had a doubling time 2–
3 hrs faster than that of the cells with miR-controls (Fig. 7C and
7D). This data suggests that miR-146a functions as a growth factor
in cervical cancer.
Discussion
In this study, we demonstrated miRNA expression profiles in
cervical cancer and HPV infection-induced pre-neoplastic lesions
in raft tissues. Although both cervical cancer tissues and HPV-
infected raft tissues with pre-neoplastic lesions showed an
upregulation of miR-15a and miR-223 and downregulation of
miR-143, miR-145, miR-218, and miR-424, the majority of the
miRNA expression showed no correlation between the two tissues
and might delineate the disease progression. However, a high level
of miR-146a expression was found to be cervical cancer-specific
since its expression was down-regulated both in normal tissues and
in HPV-infected raft tissues with pre-neoplastic lesions.
Figure 3. miRNA signatures in cervical cancer and normal cervical tissues by miRNA array analysis. Total RNA (5 mg) isolated from age-
matched normal cervical tissues (NT) and cervical cancer tissues (Ca) were analyzed by miRNA array analysis. The cancer tissue 1, 3, and 5 were
infected with HPV16 and the cancer tissue 4 was infected with HPV45. A. A clustering graph was created using a hierarchical method from those
miRNAs with signal density of more than 1000 and shows increased (red) or decreased (green) expression (P,0.05) of individual miRNA from 4 age-
matched normal and cancerous cervical tissues (Table S1). The column heading indicates individual sample code in the assay. Each row shows the
expression pattern of individual miRNA as a log2-transformed expression ratio, with the most closely related expression joined by a branch and
clustered by an average-linked algorithm. Branch lengths reflect degrees of similarity between miRNA expression patterns. Color scale on the top of
the panel represents the degree of expression based on a calibrated ratio. Green indicates lower expression compared to the mean (zero), black
indicates expression equal to the mean, and red indicates higher expression compared to the mean. B. Verification of miRNA expression profile by
northern blotting. Total cell RNA (30 mg) isolated from each tissue was probed with individual antisense oligo to each indicated miRNA. An additional
band in each blot indicates a wobble product from Dicer digestion. C. Bar graphs show the relative levels of the examined miRNAs normalized to U6
RNA in each tissue in panel B.
doi:10.1371/journal.pone.0002557.g003
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upregulation of miR-146a in cervical cancer was in particular
attractive for two reasons: (1) miR-143 and miR-145 are expressed
from the same miRNA precursor [28] and are downregulated also
in HPV-induced pre-neoplastic lesions, in our case in HPV-infected
raft tissues, suggesting that their reductiontake place in an early step
before cancer development. Downregulation of miR-143 and miR-
145 has been found in several other cancers, including colorectal
cancer [32], B-cell lymphoma [33], and recently in cervical cancer
[34,35]. Thus, our finding is important for understanding the
mechanisms by which miR-143 and miR-145 are involved in
carcinogenesis. Inhibition by miR-143 and miR-145 of HeLa cell
growth implies that miR-143 and miR-145 probably need to be
downregulatedin order for cancer growth.(2)Upregulation of miR-
146a in cervical cancer tissues, but not in HPV-induced pre-
neoplastic lesions or in cancer-derived cell lines indicates that miR-
146 expression is cervical cancer-specific. Various studies show that
miR-146a is a NF-kappaB-dependent gene [36–38]. Expression of
miR-146a appears to vary in different cancer tissues in which an
increased level of miR-146a was observed in Burkitts’ lymphoma
lines with EBV-LMP1 (latent membrane protein 1) expression
[37,38],buta decreasedlevelinhormone-refractoryprostate cancer
[39] and papillary thyroid carcinoma [40]. In cervical cancer,
upregulation of miR146a expression appears unrelated to any of
HPV gene expression since its expression was even reduced in
productively HPV-infected raft tissues. Interestingly, all cervical
Figure 4. miRNA expression from undifferentiated keratinocytes in monolayers and stratified and differentiated keratinocytes in
raft tissues. Raft tissues (cultures) with HPV18 infection were derived from human vaginal keratinocytes (HVKs) in monolayer cultures with HPV18
DNA transfection. Total cell RNA (5 mg each) extracted from each type of cells was compared in parallel for miRNA expression using miRNA array
analyses. A. A clustering graph was created by a hierarchical method from those miRNAs with a signal density of more than 1000 obtained from three
independent transfections in each group (Table S2). The graph shows decreased (green) or increased (red) expression (p,0.05) of individual miRNAs
from undifferentiated HVKs in monolayers (Mono) versus stratified and differentiated HVKs in rafts. See other details in Fig. 3A. B. Verification of
miRNA expression from undifferentiated HVKs in monolayers and stratified and differentiated HVKs in rafts by northern blotting. Total cell RNA (30 mg
each) isolated from differentiated or undifferentiated HVKs was probed with selected miRNA probes. C. Bar graphs show the relative levels of the
examined miRNAs normalized to U6 RNA in each sample in panel B. M=monolayer culture, R=raft.
doi:10.1371/journal.pone.0002557.g004
microRNA and Cervical Cancer
PLoS ONE | www.plosone.org 6 July 2008 | Volume 3 | Issue 7 | e2557cancer cell lines and a skin keratinocyte line examined contains no
detectable miR-146a, suggesting that miR-146a in cervical cancer
tissues is upregulated by a factor missing in a homogenous cell
population or is expressed by another type of cells in cancer tissues.
Thus, we conclude that upregulation of miR-146a expression in
cervical cancer is beneficial for cancer growth as introduction of
miR-146a into cancer cells increased cell doubling time and
promoted cell proliferation.
Approximately 800 human miRNAs have been predicted. Of
these, more than 450 (http://microrna.sanger.ac.uk/sequences,
2006) have now been identified in the human [41,42] [43,44] , and
their functions are beginning to be elucidated [45]. In this study,
we cloned and identified 174 miRNAs which were grouped into 46
different miRNA species. A new subspecies of miR-193, miR-
193c, was also cloned and identified from our miRNA library
screening. Screening of 10 cell lines derived from cervical cancer
or CIN tissues for expression of 10 miRNAs suggested that the
presence or absence of integrated or episomal HPV genomes has
no effect on the expression of analyzed miRNAs. Moreover, we
were unable to identify a single HPV16-derived miRNA from
HPV16
+ CaSki cells by this approach, although other nuclear
DNA viruses do encode miRNAs [46], including EBV [47];
KSHV [48–50]; HSV-1 [51,52]; and SV40 [53]. A negative
cloning for HPV16-derived miRNAs suggests that the integrated
HPV16 genome in CaSki cells appears not to express viral
miRNAs. Another study using differentiated HPV31
+ LKP1 cells
containing ,50 copies of an episomal HPV31 genome per cell
also failed to identify virus-derived miRNAs [54].
RecentreportshavesuggestedthatmiRNAscontributetoavariety
of cell functions [41] and are involved in the development of human
cancers [19]. For example, miR-32 controls cell resistance to a
retroviral infection [55]. A cluster of six miRNAs on human
chromosome 13 is regulated by c-Myc, and the c-Myc–regulated
miR-17-5p and miR-20a negatively modulate the expression of
E2F1, a transcription factor [56]. miRNAs have been also
characterized recently as potential oncogenes that promote the
development of human B-cell lymphoma (miR-17-92 cluster) [57]
and the proliferation and tumorigenesis of primary human cells (miR-
372 and miR-373) by neutralizing p53-mediated CDK inhibition
[58]. Another study suggested that overexpression of miR-17-5p,
miR-20a, miR-21, miR-92, miR-106a, and miR-155 could be
considered an miRNA signature of solid cancer [59]. In this report,
18 miRNAs were upregulated and 15 miRNAs were downregulated
in cervicalcancertissues.The increased expression ofmiR-15b, miR-
16, miR-146a, miR-155, and miR-223 that we observed in cervical
cancer tissues has also been implicated in the development of other
human cancers: miR-15 and miR-16 regulate apoptosis by targeting
BCL2 [60] and their mutation has been associated with chronic
lymphocytic leukemia [61]; miR-16 is also involved in control of
cytokine RNA instability [62]; miR-146b levels are highly increased
in papillary thyroid carcinoma [40]; miR-155 has recently been
implicated inthe development oflymphoblasticleukemia/high-grade
lymphoma [63] and lung cancer [24] and in the regulation of human
fibroblast angiotensin II type 1 receptor expression [64]; miR-223,
along with the transcription factors C/EBPa and NFI-A, participates
in regulation of granulocytic differentiation by suppressing the
transcription of NFI-A mRNA [65].
Although mature miRNAs derived from their primary tran-
scripts through Drosha and Dicer digestion in two separate
trimming reactions contain a 2-nt 39 overhang on each strand,
Dicer digestion of the pre-miRNA is not always performed
precisely. This was reflected in the miR-21 and miR-205 isolated
in this study. We found that more than 68% of the miR-21 isolated
from CaSki cells had an additional C at the 39 end and 33% of the
miR-205 isolated contained an extra U at the 39 end, but no extra
nucleotide was ever identified from the 59 ends of either miRNA.
When compared to the corresponding pre-miRNA sequence, the
additional C on the miR-21 and the U on the miR-205 were found
to be derived directly from the nucleotide 39 to the cleavage site,
suggesting that Dicer digestion has a wobble mechanism. This
observation by small RNA cloning can be further verified as
double bands for miR-21 (Fig. 5A and Fig. 7A) and for miR-205
Figure 5. Upregulation of miR-146a is cervical cancer-specific. A. Total RNAs from HVKs in two rafts and two monolayer (Mono) cultures were
compared with two cervical cancer (Ca) tissues for the expression of miR-146a by northern blotting. The expression levels of miR-21 and miR-26b
were examined as miRNA controls. Small nuclear RNA U6 was also blotted as an internal control for sample loading. B. Bar graphs show the relative
levels of the examined miRNAs normalized to U6 RNA in each sample in panel A. M=monolayer culture, R=raft.
doi:10.1371/journal.pone.0002557.g005
microRNA and Cervical Cancer
PLoS ONE | www.plosone.org 7 July 2008 | Volume 3 | Issue 7 | e2557(Fig. 2A and 2B) in northern blot analyses. Our findings are
consistent with other reports obtained from biochemical analyses
that Dicer uses a 39 end counting rule and measures a distance of
,22 nt from the 39-terminus to cleave both strands of RNA, with
1- to 2-nt shifts in the preferred cleavage position [18,66].
Materials and Methods
Cells, tissues, and raft cultures
Eight cervical cancer cell lines were used for the assays: HPV16
+
CaSki and SiHa, HPV18
+ HeLa and C4II, HPV68
+ ME180 [67],
and HPV31
+ CIN612 6E and 9E cells. Two HPV16
+ W12
subclones (20861 and 20863) originally isolated from a low-grade
cervical lesion histologically diagnosed as CIN I [26] were also
used for comparison. Among these cell lines, 20863 and 9E cells
contain an episomal form of the HPV genome, and 20861 and 6E
cells have an integrated HPV genome [68,69]. A HPV-negative
cervical cancer cell line, C33A [70], and a HPV-negative human
keratinocyte line, HaCaT [27], were also included in this study.
All cell lines, except for W12, 6E, and 9E cells, were grown in
Dulbecco’s modified Eagle’s medium (DMEM) with 10% FBS at
37uC and 5% CO2. The W12 subclones and CIN612 6E and 9E
were grown on pretreated NIH3T3 feeder cells [71]. Human
primary vaginal keratinocytes and their derived raft cultures were
prepared as described [30]. The stratified and differentiated
keratinocytes in the raft culture epidermal layer were collected free
from collagen (no fibroblasts) and frozen on dry ice for total cell
RNA preparation. HCT116 cell line, a colorectal cancer cell line,
was a gift from Dr. Bert Vogelstein of Johns Hopkins University
and grown in McCoy’s 5A medium with 10% FBS at 37uC and
5% CO2. Total cell RNA was prepared from each cell line using
TRIzol Reagent (Invitrogen, Carlsbad, CA).
Age-matched normal cervix and cervical cancer tissues were
obtained from anonymized excess cervical tissues that were no
longer needed for diagnostic or clinical purposes. Use of these
tissues was approved both by the Washington University Medical
Center Human Studies Committee and by the NIH Office of
Human Subjects Research. Each tissue was homogenized in an
Eppedorf tube in 1 ml TRIzol Reagent using an electric
homogenizer (Omni International, Marietta, GA) with a separate
disposible probe for each tissue. The isolated RNA was dissolved
in RNase-free water and stored in a 270uC freezer.
miRNA cloning from cervical cancer cells
Cloning of miRNAs from cervical cancer cells was performed as
described previously. Briefly, approximately 600 mg of total cell
RNA prepared from HPV16-positive CaSki C-2 cells [a CaSki
subclone cell line [72] was dissolved in RNA loading buffer II
(Ambion, TX) and denatured at 75uC for 5 min. The RNA
samples were then fractionated, along with
32P-labeled RNA
oligos as size markers, in a 15% denaturing polyacrylamide gel
containing 8 M urea. After the gel was exposed to an X-ray film,
the small RNAs corresponding to the size range of the 15-nt and
30-nt oligos were cut from the gel, eluted with elution buffer
(0.3 M NaCl, 0.5% SDS), and incubated overnight at 37uC.
Subsequently, the small RNAs were ethanol precipitated and
dephosphorylated with alkaline phosphatase and then ligated to a
59-phosphorylated,
32P-labeled 39 adapter (59-rUrUrUAACCGC-
GAATTCCAG-L, L represents 39 end protection with C7-amino
modifiers, rU represents ribonucleotide) with T4 RNA ligase. After
ligation, the ligated products were separated from unligated 39
adapters in a 15% denaturing polyacrylamide gel and eluted
overnight at 37uC from the gel slices with the elution buffer
described above. After ethanol precipitation, the recovered small
RNAs were phosphorylated with T4 polynucleotide kinase and
ligated with a 59 adapter (59-ACGGAATTCCTCACTrArArA-39,
rA represents ribonucleotide) in the presence of T4 RNA ligase.
The ligated RNAs were then separated from unligated 59 adapters
in a 15% denaturing polyacrylamide gel and eluted from the gel
slices as described above. Reverse transcription was then
conducted with a reverse primer (59-GACTAGCTG-
GAATTCGCGGTTAAA-39) and Superscript II (Invitrogen).
The cDNA was amplified with the first PCR primer (59-
CAGCCAACGGAATTCCTCACTAAA-39) and the reverse
primer for 20 cycles of 45 sec at 94uC, 85 sec at 50uC, and
Figure 6. Overexpression of miR-143 and miR-145 suppresses
HeLa cell growth. A. miR-143 and miR-145 are suppressive for HeLa
cell growth. Arrows indicate the time points when the cells received a
specific miRNA (30 nM) transfection. Viable cells in each group were
counted at the indicated time points. Data represent the mean6SD of
two experiments, each performed in triplicate. B. Relative levels of miR-
143 and miR-145 in HeLa cells at 96 hrs after first transient transfection.
Total cell RNA extracted was examined by miRNA ligation assay. A tRNA
level in each sample was used as a loading control.
doi:10.1371/journal.pone.0002557.g006
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pair of PCR primers (59-GACTAGCTTGGTGCCGAATTC-
GCGGTTAAA-39,5 9-GAGCCAACAGGCACCGAATTCCT
CACTAAA-39) for 10 cycles in the same conditions. The second
PCR products were digested with BanI, concatamerized with T4
DNA ligase, and cloned into a pCR2.1-TOPO vector. The
bacterial colonies were first screened with PCR using two M13
primers (59-GTAAAACGACGGCCAG-39;5 9-CAGGAAA-
CAGCTATGAC-39). Colonies containing an insert from 400 bp
to1000 bp in size were further grown and each plasmid DNA
prepared was sequenced from both directions with M13 primers.
mParaflo
TM miRNA microarray assay
A microarray assay was performed using a service provider (LC
Sciences, Houston, TX). The assay started with 5 mg of total RNA
sample. The RNA was size-fractionated using a YM-100 Microcon
centrifugal filter (GE Millipore, Billerica, MA), and the 39 ends of
the small RNAs (,300 nt) were extended with a poly(A) tail using
poly(A) polymerase. An oligonucleotide tag was then ligated to the
poly(A) tail for later fluorescent dye staining; two different tags were
used for the two RNA samples in dual-sample experiments.
Hybridization was performed overnight on a mParaflo microfluidic
chip using a microcirculation pump [73,74]. On the microfluidic
chip, each detection probe consisted of a chemically modified
nucleotide coding segment complementary to the target miRNA
(455 human miRNA [hsa-miRNA] entries in version 8.1 from
miRBase, http://microrna.sanger.ac.uk/sequences/) or other con-
trolRNAs and a spacersegment ofpolyethyleneglycol toextendthe
coding segment away from the substrate. The detection probes were
made by in situ synthesis using photogenerated reagent chemistry.
The hybridization melting temperatures were balanced by chemical
modifications of the detection probes. Hybridization was performed
in 100 mLo f6 6SSPE buffer (0.90 M NaCl, 60 mM Na2HPO4,
6 mM EDTA, pH 6.8) containing 25% formamide at 34uC. After
hybridization, the miRNAs were detected by fluorescence labeling
using tag-specific Cy3 and Cy5 dyes. Hybridization images were
collected using a laser scanner (GenePix 4000B, Molecular Device)
and digitized using Array-Pro image analysis software (Media
Cybernetics). Data were analyzed by first subtracting the back-
ground and then normalizing the signals using a locally-weighted
regressionfilter [75]. For two-colorexperiments, the ratio of the two
sets of detected signals (log2 transformed, balanced) was calculated,
and the significance of the differences were determined by t-test
analysis; significantly different signals were those with p values less
Figure 7. Overexpression of miR-146a promotes cell proliferation. A. No expression of miR-146a in cervical cancer-derived cell lines and in a
human skin-derived keratinocyte line, HaCaT cells. Total cell RNA was extracted from individual cell line and examined for miR-146a and miR-21
expression by northern blotting. U6 in each sample served as sample loading control. B. Relative level of miR-146a in HeLa and HCT116 cells at 96 hrs
after the first transfection. Total cell RNA extracted from each group was examined by northern blotting. C and D. miR-146a promotes cell
proliferation. Arrows indicate the time points when the cells received transfection with miR-146a or miR-control (30 nM). Viable cells in each group
were counted at the indicated time points. Data represent the mean6SD of two experiments, each performed in triplicate.
doi:10.1371/journal.pone.0002557.g007
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performedusingahierarchicalmethod,withanaverage linkage and
Euclidean distance metric. The clustering plots were generated
using MultiExperiment Viewer software (v4.0, 2006) from The
Institute for Genomic Research and were created from those
miRNAs with a total signal density of more than 1000.
Northern blot of small RNAs
Total cell RNA (30 mg) was resolved in a 12% or 15% (Fig. 2
only) denaturing polyacrylamide gel, transferred onto a GeneSc-
reen-Plus Hybridization Transfer membrane (NEN PerkinElmer,
Waltham, MA) in 0.56 TBE, and blotted with a
32P-labeled
miRNA-specific oligo as described [72]. After blotting, the same
membrane was stripped in 0.16 SSPE, 0.5% SDS at 85uCt o
90uC for 20 min and prehybridized with hybridization buffer
(Perfecthyb, Sigma) for 2 h and then hybridized with another
probe overnight at 40uC. The membrane was washed in 26SSPE
containing 0.5% SDS, 0.56 SSPE containing 0.5% SDS, and
0.26SSPE containing 0.1% SDS for 30 min each at 40uC, and
then exposed to a PhosphorImager screen. The image was
captured using a Molecular Dynamic PhosphorImager Storm 860
and analyzed with ImageQuant software. The oligo probes were
designed based on individual miRNA sequence information
deposited in miRBase (http://microrna.sanger.ac.uk). An anti-
sense oligo of U6 snRNA (oST197, 59-AAAATATG-
GAACGCTTCACGA-39) was used to detect U6 snRNA from
each sample as a loading control.
miRNA ligation assay
miRNA ligation assay was performed using miRtect-IT
TM
miRNA Labeling and Detection Kit (USB, Cleveland, OH).
Briefly, a detection oligo was 59 end labeled with c-
32P-ATP and
OptiKinase. The miRNA and the radiolabeled detection oligo
were captured with a miRNA-specific bridge oligo and were then
ligated with T4 DNA ligase. The ligated miRNA was separated on
a 12% denaturing polyacrylamide gel and exposed to a
PhosphorImager screen for 2.5 h. The image was captured and
analyzed as described above.
Transient miRNA transfection
Approximately 2.3610
5 HeLa and HCT116 cells were
transfected with 30 nM of individual testing miRNA precursor
or control-miRNA precursor (non-specific) purchased from
Ambion. In each miRNA transfection, cell passage and miRNA
transfection were conducted simultaneously using siPORT
TM
NeoFX
TM Transfection Agent (Ambion) according to the
manufacturer’s instruction. After 48 h, the cells were counted,
split, and transfected again with each corresponding miRNA with
the same dose. After additional 48 h, the cells were counted and
total RNA was extracted with TRIzol Reagent (Invitrogen). A
student t-test was used for statistical analysis of cell counts.
Supporting Information
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Found at: doi:10.1371/journal.pone.0002557.s001 (0.08 MB
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